Allogeneic Cell Therapy Market (By Therapy Type: Stem Cell, Non-stem Cell; By Therapeutic Area: Hematological Disorders, Dermatological Disorders) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2023-2032

The global allogeneic cell therapy market size was estimated at around USD 255.64 million in 2022 and it is projected to hit around USD 2,888.59 million by 2032, growing at a CAGR of 27.44% from 2023 to 2032.

Allogeneic Cell Therapy Market Size 2023 to 2032

Key Pointers

  • Based on the therapy type, the stem cell therapies segment dominated the market with the largest share of 77.02% in 2022. The highest market share of the segment is attributed to the increasing incidence of target diseases that can be treated with such therapies.
  • The non-stem cell therapies segment is expected to grow at the fastest CAGR of 31.37% by 2032 owing to the exponential growth in the number of CAR-T therapy clinical studies and its higher success rate.
  • The hematological disorders segment accounted for the largest market share of 58.22% in 2022. The use of allogeneic cell therapy in the treatment of hematological disorders is necessary due to the increasing prevalence of leukemia, lymphoma, and myeloma, among others. The increasing number of FDA approvals and strategic moves by key market participants are contributing to the segment's largest market share. 
  • The dermatological disorders segment is expected to witness a rapid CAGR by 2032 since there is a wide range of cell-based therapies under development for the treatment of dermatological diseases.The market is also anticipated to experience profitable growth during the forecast period due to rising awareness of allogeneic stem cell-based therapy products that can be used to treat a wide range of dermatological diseases, including atopic dermatitis, autoimmune skin disorders, skin aging, wound healing, scar therapy, and many others. 
  • North America accounted for the largest market share of 80.44% in 2022 owing to the presence of a well-established healthcare system and the increasing prevalence of chronic diseases. The region has a high demand for advanced medical treatments, including cell-based therapies, to manage chronic diseases, leading to significant market growth.
  • The Europe region is expected to see a significant growth rate in the market from 2023 to 2032, due to various factors such as the increasing investments and favorable policies implemented by governments toward the adoption of regenerative medicines.

Report Scope of the Allogeneic Cell Therapy Market

Report Coverage Details
Market Size in 2022 USD 255.64 million
Revenue Forecast by 2032 USD 2,888.59 million
Growth rate from 2023 to 2032 CAGR of 27.44%
Base Year 2022
Forecast Period 2023 to 2032
Market Analysis (Terms Used) Value (US$ Million/Billion) or (Volume/Units)
Regions Covered North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Companies Covered SSM Cardinal Glennon Children's Medical Center; Cleveland Cord Blood Center; Duke University School of Medicine; New York Blood Center; Clinimmune Labs; University of Colorado Cord Blood Bank; MD Anderson Cord Blood Bank; LifeSouth Community Blood Centers, Inc.; Bloodworks Northwest; JCR Pharmaceuticals Co., Ltd.; Sumitomo Pharma Co., Ltd.; Atara Biotherapeutics; Mallinckrodt Pharmaceuticals; Tego Science Inc; Takeda Pharmaceutical Company Limited; STEMPEUTICS RESEARCH PVT LTD; Biosolution Co., Ltd.; MEDIPOST Co., Ltd.

 

The growing incidence of chronic diseases such as cancer, cardiovascular diseases, autoimmune disorders, and genetic diseases is expected to drive the growth of the allogeneic cell therapy industry. According to estimates published by the American Cancer Society, 1.9 million new cancer cases were diagnosed in the U.S. alone in 2022, resulting in over 609,000 deaths. Moreover, the aging population worldwide is expected to contribute to a further increase in the global burden of chronic diseases. These factors indicate the critical need for advanced medical treatments, such as allogeneic cell therapy, to treat chronic diseases and improve patient outcomes.

The COVID-19 pandemic had an unfavorable impact on the allogeneic cell therapy industry, causing a decline in research and development activities. This disrupted various processes, including research, clinical trials, manufacturing, and logistics, ultimately affecting the quality of clinical evidence for cell and gene therapies. As a result, evaluating the treatment benefits and economic impacts of these therapies has become more challenging. 

However, the pandemic has also raised awareness about the use of cell therapy as a potential treatment option for COVID-19. This increasing awareness is expected to have a positive impact on the market in the coming years. For instance, in May 2020, Lineage Cell Therapeutics received USD 5 million in emergency funding from the California Institute for Regenerative Medicine (CIRM) to develop a potential vaccine against SARS-CoV-2 using VAC, their allogeneic dendritic cell therapy. 

Furthermore, the increasing need for advanced medical treatments for chronic diseases has led to a surge in clinical trials for cell therapies. According to data published by ClinicalTrials.gov, as of April 2021, there were 1,358 active cell therapy trials, representing a 43% increase from 2020 to 2021, compared to a 24% increase from 2019 to 2020. The majority of this growth has been due to CAR-T cell clinical trials, which have increased by 83%. 

Moreover, there has been a shift in the focus of clinical trials from autologous to allogeneic cell therapy, with many companies conducting clinical trials on allogeneic cell therapy candidates for various diseases, such as cancer, genetic disorders, and autoimmune diseases. This trend is expected to continue, as there is increasing interest from governments, private organizations, and biotechnology companies in the development of allogeneic cell therapies. 

Furthermore, the allogeneic cell therapy industry is expected to grow due to the increasing investments in research and development by governments and private & public organizations. For instance, in November 2022, the California Institute for Regenerative Medicine (CIRM) Board awarded over USD 6 million to Jianhua Yu at the Beckman Research Institute of City of Hope for developing a new approach to target hypoxia metastatic breast tumors with allogeneic off-the-shelf anti-EGFR CAR NK cells. This approach aims to improve the efficacy and safety of cancer therapy. 

Allogeneic Cell Therapy Market Segmentations:

By Therapy Type

  • Stem Cell Therapies
    • Hematopoietic Stem Cell Therapies
    • Mesenchymal Stem Cell Therapies
  • Non-stem Cell Therapies
    • Keratinocytes & Fibroblast-based Therapies
    • Others

By Therapeutic Area

  • Hematological Disorders
  • Dermatological Disorders
  • Others

Frequently Asked Questions

The global allogeneic cell therapy market size was reached at USD 255.64 million in 2022 and it is projected to hit around USD 2,888.59 million by 2032.

The global allogeneic cell therapy market is growing at a compound annual growth rate (CAGR) of 27.44% from 2023 to 2032.

The North America region has accounted for the largest allogeneic cell therapy market share in 2022.

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Allogeneic Cell Therapy Market 

5.1. COVID-19 Landscape: Allogeneic Cell Therapy Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Allogeneic Cell Therapy Market, By Therapy Type

8.1. Allogeneic Cell Therapy Market, by Therapy Type, 2023-2032

8.1.1. Stem Cell Therapies

8.1.1.1. Market Revenue and Forecast (2020-2032)

8.1.2. Non-stem Cell Therapies

8.1.2.1. Market Revenue and Forecast (2020-2032)

Chapter 9. Global Allogeneic Cell Therapy Market, By Therapeutic Area

9.1. Allogeneic Cell Therapy Market, by Therapeutic Area, 2023-2032

9.1.1. Hematological Disorders

9.1.1.1. Market Revenue and Forecast (2020-2032)

9.1.2. Dermatological Disorders

9.1.2.1. Market Revenue and Forecast (2020-2032)

9.1.3. Others

9.1.3.1. Market Revenue and Forecast (2020-2032)

Chapter 10. Global Allogeneic Cell Therapy Market, Regional Estimates and Trend Forecast

10.1. North America

10.1.1. Market Revenue and Forecast, by Therapy Type (2020-2032)

10.1.2. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

10.1.3. U.S.

10.1.3.1. Market Revenue and Forecast, by Therapy Type (2020-2032)

10.1.3.2. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

10.1.4. Rest of North America

10.1.4.1. Market Revenue and Forecast, by Therapy Type (2020-2032)

10.1.4.2. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

10.2. Europe

10.2.1. Market Revenue and Forecast, by Therapy Type (2020-2032)

10.2.2. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

10.2.3. UK

10.2.3.1. Market Revenue and Forecast, by Therapy Type (2020-2032)

10.2.3.2. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

10.2.4. Germany

10.2.4.1. Market Revenue and Forecast, by Therapy Type (2020-2032)

10.2.4.2. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

10.2.5. France

10.2.5.1. Market Revenue and Forecast, by Therapy Type (2020-2032)

10.2.5.2. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

10.2.6. Rest of Europe

10.2.6.1. Market Revenue and Forecast, by Therapy Type (2020-2032)

10.2.6.2. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

10.3. APAC

10.3.1. Market Revenue and Forecast, by Therapy Type (2020-2032)

10.3.2. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

10.3.3. India

10.3.3.1. Market Revenue and Forecast, by Therapy Type (2020-2032)

10.3.3.2. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

10.3.4. China

10.3.4.1. Market Revenue and Forecast, by Therapy Type (2020-2032)

10.3.4.2. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

10.3.5. Japan

10.3.5.1. Market Revenue and Forecast, by Therapy Type (2020-2032)

10.3.5.2. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

10.3.6. Rest of APAC

10.3.6.1. Market Revenue and Forecast, by Therapy Type (2020-2032)

10.3.6.2. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

10.4. MEA

10.4.1. Market Revenue and Forecast, by Therapy Type (2020-2032)

10.4.2. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

10.4.3. GCC

10.4.3.1. Market Revenue and Forecast, by Therapy Type (2020-2032)

10.4.3.2. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

10.4.4. North Africa

10.4.4.1. Market Revenue and Forecast, by Therapy Type (2020-2032)

10.4.4.2. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

10.4.5. South Africa

10.4.5.1. Market Revenue and Forecast, by Therapy Type (2020-2032)

10.4.5.2. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

10.4.6. Rest of MEA

10.4.6.1. Market Revenue and Forecast, by Therapy Type (2020-2032)

10.4.6.2. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

10.5. Latin America

10.5.1. Market Revenue and Forecast, by Therapy Type (2020-2032)

10.5.2. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

10.5.3. Brazil

10.5.3.1. Market Revenue and Forecast, by Therapy Type (2020-2032)

10.5.3.2. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

10.5.4. Rest of LATAM

10.5.4.1. Market Revenue and Forecast, by Therapy Type (2020-2032)

10.5.4.2. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

Chapter 11. Company Profiles

11.1. SSM Cardinal Glennon Children's Medical Center

11.1.1. Company Overview

11.1.2. Product Offerings

11.1.3. Financial Performance

11.1.4. Recent Initiatives

11.2. Cleveland Cord Blood Cente

11.2.1. Company Overview

11.2.2. Product Offerings

11.2.3. Financial Performance

11.2.4. Recent Initiatives

11.3. Duke University School of Medicine

11.3.1. Company Overview

11.3.2. Product Offerings

11.3.3. Financial Performance

11.3.4. Recent Initiatives

11.4. New York Blood Center

11.4.1. Company Overview

11.4.2. Product Offerings

11.4.3. Financial Performance

11.4.4. LTE Scientific

11.5. Clinimmune Labs

11.5.1. Company Overview

11.5.2. Product Offerings

11.5.3. Financial Performance

11.5.4. Recent Initiatives

11.6. University of Colorado Cord Blood Bank

11.6.1. Company Overview

11.6.2. Product Offerings

11.6.3. Financial Performance

11.6.4. Recent Initiatives

11.7. MD Anderson Cord Blood Bank

11.7.1. Company Overview

11.7.2. Product Offerings

11.7.3. Financial Performance

11.7.4. Recent Initiatives

11.8. LifeSouth Community Blood Centers, Inc.

11.8.1. Company Overview

11.8.2. Product Offerings

11.8.3. Financial Performance

11.8.4. Recent Initiatives

11.9. Bloodworks Northwest

11.9.1. Company Overview

11.9.2. Product Offerings

11.9.3. Financial Performance

11.9.4. Recent Initiatives

11.10. JCR Pharmaceuticals Co., Ltd.

11.10.1. Company Overview

11.10.2. Product Offerings

11.10.3. Financial Performance

11.10.4. Recent Initiatives

Chapter 12. Research Methodology

12.1. Primary Research

12.2. Secondary Research

12.3. Assumptions

Chapter 13. Appendix

13.1. About Us

13.2. Glossary of Terms

Proceed To Buy

USD 4500
USD 3800
USD 1900
USD 1200

Customization Offered

  • check-imgCross-segment Market Size and Analysis for Mentioned Segments
  • check-imgAdditional Company Profiles (Upto 5 With No Cost)
  • check-img Additional Countries (Apart From Mentioned Countries)
  • check-img Country/Region-specific Report
  • check-img Go To Market Strategy
  • check-imgRegion Specific Market Dynamics
  • check-imgRegion Level Market Share
  • check-img Import Export Analysis
  • check-imgProduction Analysis
  • check-imgOthers